The global sulphonamides market size is worth US$ 107.34 Mn in 2022. The market is projected to witness a CAGR of 4.5% over the forecast period, to achieve a market valuation of US$ 166.69 Mn by 2032. The growth of the market can be credited to the rising efforts by key players to formulate diagnostic tools to check infections.
The market for sulphonamides is expected to be driven by the increasing occurrence of multiple types of infections affecting all age groups. For instance, in March 2022, the publication of an article titled ‘Prevalence of most common skin diseases in Europe: a population-based study, in the Wiley Online Library estimated that over 94 million Europeans suffer from uneasy skin sensations, such as burning, itch, or dryness. Further, the most recurrent conditions included fungal skin infections, acne, and atopic dermatitis or eczema.
Similarly, the greater prevalence of an extensive range of diseases like skin infections, urinary tract infections, gastrointestinal tract (GIT), and respiratory tract infections contribute to the heightened demand for sulphonamides globally.
Attributes
Details
sulphonamides Market Value (2022)
US$ 107.34 Million
sulphonamides Market Forecast Value (2032)
US$ 166.69 Million
sulphonamides Market CAGR (2022 to 2032)
4.5%
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Emerging Technologies Serve as a Boon to the Market
Further, the surging use of advanced technologies like bioinformatics, high throughput, and combinatorial chemistry to identify a better drug candidate is also helping the market witness a progressive growth trajectory. The growing demand for emerging technologies that help the drug discovery process to provide more accuracy, and become refined and less time-consuming, is escalating market development. The rising demand for high-throughput screening, an extensively utilized drug discovery technology due to its automation, imaging hardware and software, and multi-detector readers, is propelling the market growth.
The market is predicted to be positively affected by the increasing focus of prominent players on the formulation of diagnostics tools to check urinary tract infections (UTIs). For instance, Sysmex Corporation announced in January 2020 that it had agreed to invest in Astrego Diagnostics AB. With this investment, Sysmex intends to commercialize a rapid drug test that the latter has been developing for UTIs.
Additionally, a substantial amount of different sulfonamide drug formulations are available at a reasonable price, and the pervasiveness of complicated UTIs are predicted to fuel the market growth over the forecast period. Moreover, the rising drug-resistant bacteria and exponential use of antibiotics are propelling several physicians to prescribe sulfonamides to cure UTI cases.
Sulfonamides are organic sulfur compounds that contain the radical SO2NH2 (the amide of sulfonic acid), which are also known as sulfa drugs or sulpha drugs. These are first anti-microbial drugs developed to treat bacterial infections in humans and animals.
Sulfonamides interfere in folic acid synthesis process in bacterial cell by competitive inhibition of dihydropteroate synthetase (DHPS) enzyme competing with para amino benzoic acid (PABA). Folic acid is a precursor of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) formation in bacterial cell.
Sulfonamides limits the growth of bacteria and thus sulfonamides act as bacteriostatic agents. A few sulfonamides are highly water-soluble such as sulfisoxazole (sulfafurazole) and sulfasomidine, which are rapidly excreted through the urinary tract (more than 90% in 24 hr) mostly in an unchanged drug form; due to this pharmacokinetic property these sulfonamides are primarily used to treat urinary tract infections (UTI’s).
In addition, some of the sulfonamide derivatives, such as sulfaguanidine, are insoluble in nature thus they are not absorbed from the gastro intestinal (GI) tract (less than 5%), therefore, these sulphonamides are used for treatment of ulcerative colitis.
Bayer AG was the first company who started experimenting with Prontosil in 1932. Many people are allergic to sulfa drugs and thus sulfonamides are prescribed with caution. Sulfonamides have potential to cause fatal side effects including urinary tract disorders, haemopoietic disorders, hyper sensitivity reactions and porphyria.
Most serious side effects include toxic epidermal necrosis, hemolytic anemia, agranulocytosis, fulminant hepatic necrosis, thrombocytopenia and Stevens Johnson syndrome.
Increasing prevalence of chronic diseases worldwide and the substantial availability of various sulfonamide drug formulations at reasonable price to meet the ever-growing demand are the major factors contributing to the growth of the global sulfonamides market.
In addition, increasing R&D activities in pharmaceutical companies is resulting in novel and improved classes of sulfonamides with improved therapeutic activity is another major driver, fueling the global sulfonamides market growth over the forecast period.
However, increasing side effects associated with the use of sulfa drugs such as urinary tract disorders, kernicterus and hypersensitivity and increasing use of broad spectrum antibiotics with lesser side effects such as quinolones, macrolides are expected to restrain the growth of global sulfonamides market.
Geographically global sulfonamides market has been segmented into North America, Latin America, Europe, Asia-Pacific & Japan, Middle East Africa regions. North America region has been estimated as most dominant region in the global sulfonamides market owing to presence of harmonized regulatory structure, high rates of awareness regarding sulpha drugs and its therapeutic uses, and highly developed healthcare infrastructure.
Asia-Pacific & Japan is a lucrative market for global sulfonamides. Countries in the Asia Pacific regions include, greater China and India together account for largest population pool in the world and thereby have large pool of geriatric population in addition to rapidly increasing medical tourism industry and increasing healthcare spending are some of the factors that are expected to fuel the growth of sulfonamides market in the region.
Some of the key companies contributing to global sulfonamides market are Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals, Inc., Bayer AG, GlaxoSmithKline plc, King Pharmaceuticals, Inc., Mylan Pharmaceuticals, Novartis International AG, Pfizer, Inc., Par Pharmaceutical, Inc., Roche Holding AG, Sanofi Aventis, Stiefel Laboratories, Inc., and Teva Pharmaceuticals,.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology, material and applications.
The report covers exhaustiveanalysis on
Sulfonamides Market Segments
Sulfonamides Market Dynamics
Historical Actual Market Size, 2014 - 2015
Sulfonamides Market Size & Forecast 2016 to 2026
Supply & Demand
Sulfonamides Market Current Trends/Issues/Challenges
Find your sweet spots for generating winning opportunities in this market.
Regional analysis includes
North America
Latin America
Europe
Asia Pacific & Japan
Middle East and Africa
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Sulphonamides Market
Based on type of administration, global sulfonamide market is classified as follows:
Oral
Orally Absorbable Sulfonamide
Short Acting (sulafadiazine, sulfacytine, sulfamethizole, sulfisoxazole)
